Phase 2 ADHD Trial, Recruiting NCT07592390 Sponsor: Universidade do Sul de Santa Catarina Condition: ADHD
Back to Adhd

Phase 2 ADHD Trial, Recruiting

NCT07592390
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are a teenager between 12 and 17 years old
  • You have been diagnosed with ADHD, confirmed using a specific standard questionnaire called the SNAP-IV
  • You have previously tried treatments for ADHD (either medication or other types of therapy) but did not see significant improvement in your symptoms
  • You do not have any serious mental health conditions or major physical health problems alongside your ADHD
  • Both you and your parent or legal guardian are able to understand what the study involves
  • Your parent or legal guardian is willing to sign a consent form, and you are willing to agree to take part

Who may not be able to join:

  • You have used any cannabis-based products (natural or synthetic) in the 30 days before the study starts
  • You have a history of bad reactions to cannabis-based products, such as confusion, paranoia, severe drowsiness, itching, vomiting, diarrhea, or seizures
  • You have a significant physical health condition (confirm with trial site)
  • You have a serious mental health disorder that is not related to ADHD
  • You have moderate to severe difficulties with thinking, learning, or memory
  • You are unwilling or unable to complete the study activities or fill in the required questionnaires

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 27 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: +55 48 9 8833-6460

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
Universidade do Sul de Santa Catarina
Registry
ClinicalTrials.gov
Start date
1 May 2026
Est. completion
18 December 2026

Where this trial is recruiting

🇧🇷 Brazil

Primary endpoints

Change in Attention-Deficit/Hyperactivity Disorder symptom severity assessed by the Swanson, Nolan and Pelham Questionnaire, version IV

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov